{"nctId":"NCT03691662","briefTitle":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","startDateStruct":{"date":"2018-09-27","type":"ACTUAL"},"conditions":["Glaucoma and Ocular Hypertension"],"count":417,"armGroups":[{"label":"DE-117 Ophthalmic Solution","type":"EXPERIMENTAL","interventionNames":["Drug: DE-117 Ophthalmic Solution"]},{"label":"Timolol Maleate Ophthalmic Solution 0.5%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Timolol Maleate Ophthalmic Solution 0.5%"]}],"interventions":[{"name":"DE-117 Ophthalmic Solution","otherNames":[]},{"name":"Timolol Maleate Ophthalmic Solution 0.5%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nâ€¢ glaucoma or ocular hypertension\n\nExclusion Criteria:\n\n* Females who are pregnant, nursing, or planning a pregnancy\n* Any corneal abnormality or other condition interfering with or preventing reliable tonometric measurements","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressure (IOP) at Week 1","description":"Intraocular Pressure: Analysis of IOP Score using Mixed Model for Repeated Measures (MMRM) on Observed Cases (Study Eye, Full Analysis Set). Intraocular Pressure (IOP), the fluid pressure inside the eye was measured with calibrated Goldmann applanation tonometer in millimeters mercury (mmHg) at 3 time points throughout the day.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"0.23"},{"groupId":"OG001","value":"19.7","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"0.22"},{"groupId":"OG001","value":"18.9","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"0.23"},{"groupId":"OG001","value":"18.6","spread":"0.22"}]}]}]},{"type":"PRIMARY","title":"Intraocular Pressure (IOP) at Week 6","description":"Intraocular Pressure: Analysis of IOP Score using Mixed Model for Repeated Measures (MMRM) on Observed Cases (Study Eye, Full Analysis Set). Intraocular Pressure (IOP), the fluid pressure inside the eye was measured with calibrated Goldmann applanation tonometer in millimeters mercury (mmHg) at 3 time points throughout the day.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":"0.22"},{"groupId":"OG001","value":"19.5","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"0.20"},{"groupId":"OG001","value":"18.8","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"0.21"},{"groupId":"OG001","value":"18.8","spread":"0.21"}]}]}]},{"type":"PRIMARY","title":"Intraocular Pressure (IOP) at Month 3","description":"Intraocular Pressure: Analysis of IOP Score using Mixed Model for Repeated Measures (MMRM) on Observed Cases (Study Eye, Full Analysis Set). Intraocular Pressure (IOP), the fluid pressure inside the eye was measured with calibrated Goldmann applanation tonometer in millimeters mercury (mmHg) at 3 time points throughout the day.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":"0.22"},{"groupId":"OG001","value":"19.6","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"0.23"},{"groupId":"OG001","value":"18.9","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":"0.23"},{"groupId":"OG001","value":"19.0","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Mean Diurnal Intraocular Pressure (IOP) at Month 3 (First Key Secondary Endpoint)","description":"To determine if the mean diurnal IOP reduction with DE-117 ophthalmic solution 0.002% is superior to that of Timolol Maleate ophthalmic solution 0.5% at Month 3 in subjects with OAG or OHT. Mean Diurnal IOP is defined as the average IOP of all three timepoints (8AM, 10AM and 4PM) at Month 3.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"0.19"},{"groupId":"OG001","value":"19.2","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure (IOP) at Week 1 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)","description":"Intraocular Pressure (IOP) at Week 1 with baseline mean diurnal IOP less than 25 mmHg (Second Key Secondary Endpoint)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"0.28"},{"groupId":"OG001","value":"19.1","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"0.27"},{"groupId":"OG001","value":"18.2","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":"0.27"},{"groupId":"OG001","value":"18.0","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure (IOP) at Week 6 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)","description":"Intraocular Pressure (IOP) at Week 6 with baseline mean diurnal IOP less than 25 mmHg (Second Key Secondary Endpoint)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"0.28"},{"groupId":"OG001","value":"18.9","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":"0.25"},{"groupId":"OG001","value":"18.2","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":"0.26"},{"groupId":"OG001","value":"18.0","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure (IOP) at Month 3 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)","description":"Intraocular Pressure (IOP) at Month 3 with baseline mean diurnal IOP less than 25 mmHg (Second Key Secondary Endpoint)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":"0.29"},{"groupId":"OG001","value":"18.8","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"0.28"},{"groupId":"OG001","value":"18.0","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"0.28"},{"groupId":"OG001","value":"18.0","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Mean Diurnal Intraocular Pressure (IOP) at Week 1 (Third Key Secondary Endpoint)","description":"The third key secondary endpoint, mean diurnal IOP at Week 1, the hypothesis of superiority of DE-117 to timolol was tested. Analysis using MMRM on Observed Cases.\n\nMean Diurnal IOP is defined as the average IOP of all three timepoints (8AM, 10AM and 4PM) at week 1.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":"0.20"},{"groupId":"OG001","value":"19.1","spread":"0.20"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":204},"commonTop":["Instillation site pain","Conjunctival hyperaemia","Photophobia","Vision blurred","Upper respiratory tract infection"]}}}